HUMAN UMBILICAL CORD BLOOD-DERIVED MONOCYTES FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Nov 23, 2016
filing date -
Nov 23, 2015
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Human umbilical cord blood-derived monocytes that markedly promote Aβ clearance through heterodimerization of sAPPα with Aβ and resultant sAPPα production for prevention or treatment of Alzheimer's disease and other neurodegenerative disorders (including stroke and TBI). It was discovered that multiple low-dose infusions of human umbilical cord blood cells (HUCBCs) ameliorate cognitive impairments and reduce Aβ-associated neuropathology in PSAPP transgenic mice, which markedly promotes amyloid precursor protein (APP) α-cleavage and resultant sAPPα production for pharmaceutical purposes, in particular for treating or slowing the progression of Alzheimer's disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully